Population pharmacokinetic‐pharmacodynamic model‐based exploration of alternative ustekinumab dosage regimens for patients with Crohn's disease

Zhigang Wang(Dalian Medical University), Erwin Dreesen(KU Leuven), Séverine Vermeire(KU Leuven), Paul Declerck(KU Leuven), João Sabino(KU Leuven), Bram Verstockt(Universitair Ziekenhuis Leuven), Marc Ferrante(Universitair Ziekenhuis Leuven)
British Journal of Clinical Pharmacology
July 2, 2021
10.1111/bcp.14971
Cited by 32

Related Papers

Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
A decrease of the butyrate-producing species <i>Roseburia hominis</i> and <i>Faecalibacterium prausnitzii</i> defines dysbiosis in patients with ulcerative colitis
|Gut|2013|1.9k
ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications
|Journal of Crohn s and Colitis|2018|1.8k
Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
|New England Journal of Medicine|2016|1.8k
ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment
|Journal of Crohn s and Colitis|2019|1.4k